+ Watch NVS
on My Watchlist
Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.
After a good run in the past couple months, NVS looks poised to underperform the S&P. Not that I think its going to take a fall, more so that the S&P will be playing catchup for the next couple of months while NVS hangs around somewhat.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions